Eisai and Arena Pharmaceuticals announced lorcaserin publication of the post-hoc analysis of the phase ...

Woodcliff Lake, NJ, and SAN DIEGO, July 30, 2014 / PRNewswire / - Eisai Inc. and Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) announced today an article about the post-hoc analysis of three pivotal Phase 3 studies lorcaserin title "Of course, the loss of the early lorcaserin weight, diet, exercise, and as a predictor of week 52 results of weight loss," was recently published in the online edition of Obesity, the official journal of the Society published obesity counterpart. The purpose of this test is to determine whether it predict an initial phase of treatment, the treated in a year lorcaserin patients or to greater weight loss of 5%.

About Belviq (R) (lorcaserin HCl) CIV

Belviq an agonist of the serotonin receptor 2C approved in the U.S. as an adjunct to diet reduce calories and increase physical activity in chronic weight control in adults with a Body Mass Index (BMI) of 30 kg / m (2) or more (obese ) or BMI of 27 kg / m (2) or more (overweight) with at least one health problem to lose weight, such as high blood pressure, cholesterol or diabetes 2 safety and efficacy from the concurrent Belviq with other products for weight loss, including prescription drug formulation (for example, phentermine). Type, over-the-counter medications and herbal supplements have not been established. The effect of Belviq on cardiovascular morbidity and mortality has not been established.

Belviq to reduce and promote satiety by selective activation of serotonin 2C receptor in the brain, the food intake. The exact mechanism of action is not known Belviq.

Belviq approved by the U.S. Food and Drug Administration (FDA). Eisai Belviq markets and distributes in the United States, and the arena manufactures and supplies commercial installation of the final product in Switzerland.

For more information on Belviq click here for more product information approved by the FDA in the U.S., or visit www.BELVIQ.com.

Important Safety Information

Cons-information

     - Belviq should not be used during pregnancy or by women who are considering hit         to become pregnant. 

Warnings and Precautions

     - Is a serotonergic drug Belviq. In potentially         Serotonin syndrome or neuroleptic malignant syndrome life threatening         Reactions (NMS), as reported for the use of serotonergic         including, but not limited to, limited serotonin and norepinephrine         Reuptake inhibitors and inhibitors of serotonin reuptake,         tricyclic antidepressants, bupropion, triptans, dietary supplements, such as for         as a condiment and tryptophan San Juan, drugs that alter the metabolism of         Serotonin (including MAOIs), dextromethorphan,         Lithium, tramadol, antipsychotics and other dopamine antagonists,         particularly when they are used in combination. Patients should be monitored         the occurrence of the symptoms of serotonin syndrome or NMS-like reactions,         including agitation, hallucinations, coma, tachycardia, labile blood         Pressure, hyperthermia, hyperreflexia, incoordination, nausea, vomiting,         Diarrhea and muscle stiffness. Treatment Belviq and escort         serotonergic or antidopaminergic agents must stop         immediately if the above and symptomatic events, BH         Treatment should be initiated.         - Patients should not take Belviq in combination with drugs that have been the         with valvular heart disease (eg, cabergoline) assigned. Clinical         Tests, 2.4% of patients and 2.0% of patients Belviq         Placebo developed valvular regurgitation: none of these patients were         symptomatic. Belviq should be used with caution in patients         congestive heart failure (CHF). Patients who develop signs and symptoms         Heart valve disease include shortness of breath, edema dependent, CHF, or         new heart murmur should be the evaluation and adjustment of Belviq         be considered.         - Impaired attention, memory, dizziness, confusion and fatigue         the Belviq was observed in patients reported. Patients should not drive         or operate machinery until you know how Belviq concerns.         - 10 mg twice daily recommended dose should not be exceeded, as         Higher doses can cause euphoria, hallucinations, and dissociation. Monitoring         Patients to the development or worsening of depression, suicide         Thoughts or behavior, and / or mood swings. Visit Belviq         Patients to develop suicidal thoughts or behaviors.         - Weight loss may increase the risk of hypoglycemia in patients with type 2 diabetes         Diabetes mellitus who are treated with antidiabetic agents, so         Measurement of blood glucose levels before and during treatment with Belviq         recommended. Lower doses of antidiabetic agents or changes         Drug should be considered in the treatment.         - Men who suffer priapism and must be stopped immediately Belviq         Seek emergency medical attention. Belviq should be used with caution         Drugs for the treatment of erectile dysfunction. Belviq be used with caution         Men, the conditions that they predispose them to priapism (such as         Sickle cell anemia, multiple myeloma or leukemia), or in men with         Anatomical deformity of the penis (such as angulation, cavernous fibrosis,         or Peyronie's disease).         - Because Belviq can cause a slow heart rate that should be used with caution to         Patients with a history of bradycardia or heart block more         first class.         - Consider monitoring changes in the CBC, excess prolactin and lungs         Hypertension. 

The most common side effects

     - In patients without diabetes: headache (17%), dizziness (9%), fatigue         (7%), nausea (8%), dry mouth (5%) and constipation (6%).         - In patients with diabetes: hypoglycemia (29%), headache (15%), back pain         (12%), cough (8%) and fatigue (7%). 

Care

     - Belviq should not be used by breast-feeding women. 

Belviq (R) is controlled by the federal government, which can lead to abuse or drug addiction.

About Eisai Inc.

In Eisai Inc., care of human health is our goal. We give our first thought to patients and their families and contribute to improving the health care providing. As U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co., Ltd., have a passionate commitment to patient care is the driving force behind our efforts to help, address unmet medical needs. We are a fully integrated pharmaceutical company in the discovery, clinical skills, manufacturing and marketing. Our focus areas of commercial interest are oncology and specialty care (Alzheimer's disease, epilepsy and metabolic disorders). For more information about Eisai, Inc., visit us at http://us.eisai.com.

Eisai Inc. has subsidiaries that are part of a global organization for the creation of products, the R & D facilities in Massachusetts, New Jersey, North Carolina and Pennsylvania as well as implementation of a global organization, the chain includes means are manufacturing in Maryland and North Carolina. Areas of R & D worldwide Eisai nearby are neuroscience; Oncology; Metabolic disorders; vascular, inflammatory and immunological reaction; and antibody-based programs.

About Arena Pharmaceuticals

Arena takes up the challenge of improving the health and tries to bring innovative drugs against G-protein-coupled receptors patient. Arena based on the discovery, development and commercialization of additional medicines to address unmet medical needs aligned. Arena of U.S. operations in San Diego, California, and its activities outside the United States, including commercial production facility in Zofingen, Switzerland. For more information, please visit the website at www.arenapharm.com Arena.

Arena has Belviq Eisai Inc. and Eisai Co., granted exclusive rights to market and distribute Ltd. for the United States and most other areas around the world.

Arena Pharmaceuticals (R) and Arena (R) are registered service marks of Arena Pharmaceuticals, Inc. Belviq (R) is a registered trademark of Arena Pharmaceuticals GmbH.

Forward-Looking Statements

Certain statements contained in this press release are forward-looking statements that involve various risks and uncertainties that include forward-looking statements. These statements include statements regarding the therapeutic indication, use, safety, efficacy, mechanism of action and potential of lorcaserin or Belviq; the importance of post-hoc analyzes and results; Rights and obligations under the supply and marketing agreement between Arena and Eisai; the challenge of improving health; To bring innovative drugs to patients; to discover and discussions, plans, objectives, strategies, expectations, development programs and ice research, and the ability and to develop and commercialize compounds Drugs. For such statements, Arena claims the protection of the Private Securities Litigation Reform Act of 1995. Actual events or results may differ materially from Arena's expectations. Factors that cause actual results to differ materially from these statements include Arena, but the following are not limited to: risks associated with the drug market, including regulatory issues, production, supply and marketing and the availability and use of Belviq; Cash and Belviq income, including the impact of competition; Income Arena is based in part on estimates, judgments and estimates and incorrect criteria or disagreement on accounting policies and estimates can lead to changes in the direction of the arena based or previously reported results; the timing and results of regulatory review Belviq is uncertain and can not text or other other area be approved for any indication for marketing in combination with another drug for a different indication or use, if it is expected or not; Regulatory decisions in one jurisdiction can affect other

Regulatory decisions and business prospects of the track; government and commercial reimbursement and pricing decisions; Risks associated to cooperation agreements; the timing and receipt of payments and fees, if any, employees; Input or modification or termination of cooperation agreements; unexpected new data or unfavorable; clinical and non-clinical data extensive and detailed, and regulatory agencies interpret differently or assess the importance of data to different conclusions reach arena or other additional information to request additional recommendations or their guidance or requirements need to change before or after approval; Data and other information in relation to a part of the research and development arena regulatory requirements or sufficient (or Arena or an employee can not sue) research and development, approval or verification of further marketing to meet not; Arena ability to obtain and defend patents; At present, the success and the costs of research and development of the arena; Results of clinical trials and other studies are subject to different interpretations and may not be indicative of future results; clinical trials and other studies can not or do not expect or to carry out at this time; sufficient resources; and satisfactory resolution of legal proceedings or disputes with others. Other factors that could differ materially from those expressed in the forward-looking statements or the actual results are disclosed in Arena documents with the Securities and Exchange Arena. These forward-looking statements represent Arena judgment from the date of publication. Arena disclaims any intent or obligation to update these forward-looking statements, unless required by applicable law.

     Contacts: Eisai Inc.      Investor questions: questions from the media:   Alex Scott Laurie Landau   alex_scott@eisai.com Laurie_Landau@eisai.com   201.746.2177 201.746.2510      Contact: Arena Pharmaceuticals, Inc.      Craig M. Audet, Ph.D., Vice President David Schull, President   President   Operations and Head of Global Regulatory david.schull @ russopartnersllc.com   Business   caudet@arenapharm.com 858.717.2310   858.453.7200, ext. 1612    

SOURCE Arena Pharmaceuticals, Inc.

/ Web Site: http://www.arenapharm.com

The news service of the Wall Street Journal has not participated in the creation of this content.